-
公开(公告)号：US20070148237A1
公开(公告)日：2007-06-28
申请号：US11563618
申请日：2006-11-27
申请人： Anthony McKinney , Gary Tollefson , Simon Yau , Ronald Vladyka , Rick Soltero
发明人： Anthony McKinney , Gary Tollefson , Simon Yau , Ronald Vladyka , Rick Soltero
CPC分类号： A61K31/423 , A61K9/0002 , A61K9/1652 , A61K9/2018 , A61K9/2054 , A61K9/2077 , A61K9/5084 , A61K31/137 , A61K31/42 , A61K31/485
摘要： Pharmaceutical formulations comprise sustained-release zonisamide. Methods of preparing such pharmaceutical formulations involve intermixing zonisamide with a suitable excipient configured to control the dissolution profile of the zonisamide. Methods of treatment involve administering the pharmaceutical formulations to patients in need of such treatment.
摘要翻译： 药物制剂包含缓释唑尼沙胺。 制备这种药物制剂的方法包括将唑尼沙胺与配制成控制唑尼沙胺的溶出曲线的合适赋形剂混合。 治疗方法包括向需要这种治疗的患者施用药物制剂。
-
2.发明授权Granulate formulation of pirfenidone and pharmaceutically acceptable excipients 有权吡非尼酮和药学上可接受的赋形剂的颗粒制剂公开(公告)号：US08383150B2
公开(公告)日：2013-02-26
申请号：US13162048
申请日：2011-06-16
CPC分类号： A61K9/4841 , A61K9/4858 , A61K9/4866 , A61K31/4412 , A61K31/4418 , Y02A50/411
摘要： A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need.
摘要翻译： 提供吡非尼酮的胶囊制剂，其包括药学上可接受的赋形剂。 在一个实施方案中，该胶囊制剂能够在患者体内维持所需的药代动力学反应。 还提供了通过将这种制剂的吡非尼酮胶囊给予需要的患者来治疗纤维化病症和其它细胞因子介导的病症的方法。
-
3.发明申请Granulate Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients 有权吡非尼酮和药学上可接受的赋形剂的颗粒剂配方公开(公告)号：US20120015984A1
公开(公告)日：2012-01-19
申请号：US13162048
申请日：2011-06-16
IPC分类号： A61K31/4418 , A61P9/00 , A61P17/02 , A61P11/06 , A61P1/16 , A61P25/00 , A61P19/02 , A61P11/00 , A61P17/00
CPC分类号： A61K9/4841 , A61K9/4858 , A61K9/4866 , A61K31/4412 , A61K31/4418 , Y02A50/411
摘要： A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need.
摘要翻译： 提供吡非尼酮的胶囊制剂，其包括药学上可接受的赋形剂。 在一个实施方案中，该胶囊制剂能够在患者体内维持所需的药代动力学反应。 还提供了通过将这种制剂的吡非尼酮胶囊给予需要的患者来治疗纤维化病症和其它细胞因子介导的病症的方法。
-
4.发明申请Capsule Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients 有权吡非尼酮和药学上可接受的赋形剂的胶囊制剂公开(公告)号：US20090191265A1
公开(公告)日：2009-07-30
申请号：US12426182
申请日：2009-04-17
IPC分类号： A61K9/48 , A61K31/4402 , A61P1/00
CPC分类号： A61K9/4841 , A61K9/4858 , A61K9/4866 , A61K31/4412 , A61K31/4418 , Y02A50/411
摘要： A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need.
摘要翻译： 提供吡非尼酮的胶囊制剂，其包括药学上可接受的赋形剂。 在一个实施方案中，该胶囊制剂能够在患者体内维持所需的药代动力学反应。 还提供了通过将这种制剂的吡非尼酮胶囊给予需要的患者来治疗纤维化病症和其它细胞因子介导的病症的方法。
-
5.发明授权Capsule formulation of pirfenidone and pharmaceutically acceptable excipients 有权吡非尼酮和药学上可接受的赋形剂的胶囊制剂公开(公告)号：US07988994B2
公开(公告)日：2011-08-02
申请号：US12067712
申请日：2006-09-22
CPC分类号： A61K9/4841 , A61K9/4858 , A61K9/4866 , A61K31/4412 , A61K31/4418 , Y02A50/411
摘要： A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need.
摘要翻译： 提供吡非尼酮的胶囊制剂，其包括药学上可接受的赋形剂。 在一个实施方案中，该胶囊制剂能够在患者体内维持所需的药代动力学反应。 还提供了通过将这种制剂的吡非尼酮胶囊给予需要的患者来治疗纤维化病症和其它细胞因子介导的病症的方法。
-
6.发明授权Capsule formulation of pirfenidone and pharmaceutically acceptable excipients 有权吡非尼酮和药学上可接受的赋形剂的胶囊制剂公开(公告)号：US07767225B2
公开(公告)日：2010-08-03
申请号：US12426182
申请日：2009-04-17
CPC分类号： A61K9/4841 , A61K9/4858 , A61K9/4866 , A61K31/4412 , A61K31/4418 , Y02A50/411
摘要： A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need.
摘要翻译： 提供吡非尼酮的胶囊制剂，其包括药学上可接受的赋形剂。 在一个实施方案中，该胶囊制剂能够在患者体内维持所需的药代动力学反应。 还提供了通过将这种制剂的吡非尼酮胶囊给予需要的患者来治疗纤维化病症和其它细胞因子介导的病症的方法。
-
7.发明申请公开(公告)号：US20100152250A1
公开(公告)日：2010-06-17
申请号：US12067712
申请日：2006-09-22
IPC分类号： A61K31/4412 , A61P43/00
CPC分类号： A61K9/4841 , A61K9/4858 , A61K9/4866 , A61K31/4412 , A61K31/4418 , Y02A50/411
摘要： A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need.
摘要翻译： 提供吡非尼酮的胶囊制剂，其包括药学上可接受的赋形剂。 在一个实施方案中，该胶囊制剂能够在患者体内维持所需的药代动力学反应。 还提供了通过将这种制剂的吡非尼酮胶囊给予需要的患者来治疗纤维化病症和其它细胞因子介导的病症的方法。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.037 秒)
